guest ::
| Home > Publications database > T Cells: Friends and Foes in NASH Pathogenesis and Hepatocarcinogenesis. |
| Home > Publications database > T Cells: Friends and Foes in NASH Pathogenesis and Hepatocarcinogenesis. |
| Journal Article (Review Article) | DKFZ-2022-00109 |
; ;
2022
Wiley Interscience
New York [u.a.]
This record in other databases: 
Please use a persistent id in citations: doi:10.1002/hep.32336
Abstract: In association with the pandemic spreading of obesity and metabolic syndrome, the prevalence of NAFLD-related HCC is increasing almost exponentially. In recent years, many of the underlining multi-factorial causes of NAFLD have been identified, and the cellular mechanisms sustaining disease development have been dissected up to single-cell level. However, there is still an urgent need to provide clinicians with more therapeutic targets, with particular attention on NAFLD-induced HCC, where immune check-point inhibitors do not work as efficiently. Whereas much effort has been invested in elucidating the role of the innate immune response in the hepatic NAFLD microenvironment, only in the last decade novel critical roles were unraveled for T cells in driving chronic inflammation toward HCC. The metabolic and immune-microenvironment interact to recreate a tumor-promoting and immune-suppressive terrain, responsible for the resistance to anti-cancer therapy. In this article, we will review the specific functions of several T-cell populations involved in NAFLD and NAFLD-driven HCC. We will illustrate the cellular cross talk with other immune cells, the regulatory networks or stimulatory effects of these interactions and the role of the metabolic microenvironment in influencing immune-cell functionality. Finally, we will present the pros and cons of the current therapeutic strategies against NAFLD-related HCC and delineate possible novel approaches for the future.
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Wiley ; Essential Science Indicators ; IF >= 15 ; JCR ; Nationallizenz
; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
